This document provides a weekly summary of news and financial market performance in the healthcare industry: - AstraZeneca sold marketing rights to anesthetics for up to $770 million. Elekta will distribute Koold Medical's brachytherapy applicators in the US. Gerresheimer extended its syringe line. - Bristol-Myers reported positive phase 2 data for Opdivo. Merck acquired Afferent Pharmaceuticals. Thermo Fisher partnered with Cytonome. UnitedHealth appointed a new CFO. - Indivior and Orion were top European performers this week. Novo Nordisk and Stada were worst performers. Asia Pacific saw the largest weekly decline at -4.

1. Contact: Harald Schelenz Linkedin: https://de.linkedin.com/in/haraldschelenz
Mail: hs.healthcarenews@gmail.com Xing: https://www.xing.com/profile/Harald_Schelenz
page1
Focus on Europe
Focus on North America
Focus on Asia Pacific
AstraZeneca has sold the marketing rights to a portfolio of anesthetics for up to $770 million in the
so-called externalisation deal to raise funds for investment in new drugs. (economictimes.com)
Elekta e tered i to a agree e t to ser e as the sole distri utor of Ko old Medi al’s ra h therap
applicators in the United States. (businesswire.com)
Gerresheimer has extended its range of cyclo olefin polymer syringes by combining its glass ready-to-
fill RTF o ept ith ClearJe t to reate the e G RTF ClearJe t ra d. (plasteurope.com)
Novo Nordisk presented its new findings from the two-phase 3b SWITCH trials on Tresiba which
showed significantly lower rates of hypoglycaemia than insulin. (reuters.com)
Roche has been granted EU approval for a second indication of its Gazyvaro product adding follicular
lymphoma to current use in chronic lymphocytic leukaemia. (pmlive.com)
UCB’s psoriatic arthritis candidate bimekizumab has shown fast and sustained efficacy in a Phase Ib
study regarding pharmacokinetics, safety and tolerability. (thepharmaletter.com)
Weekly News Wrap-Up: HEALTH CARE Industry
No. 16
2016-06-18
Astellas AstraZeneca Bristol-Myers Daiichi Sankyo Elekta Gerresheimer Merck & Co.
Novo Nordisk Roche Terumo Thermo Fisher Scientific UCB UnitedHealth Group Valeant
SPOTLIGHT
COMPANY NEWS
Bristol-Myers announced the phase 2 data for its Opdivo studies. It says that Opdivo demonstrated
an objective response rate of 66.3% in classical Hodgkin lymphoma patients. (reuters.com)
Merck & Co. will acquire Afferent Pharmaceuticals for up to $1.25 billion in a deal that expands the
phar a gia t’s pipeli e ith a didates for treati g euroge i o ditio s. (genengnews.com)
Thermo Fisher Scientific has announced a strategic partnership with Cytonome/ST, a Boston-based
cell sorting technology company, to co-develop a flow cytometry technology. (genomeweb.com)
UnitedHealth Group appoints John Rex as chief financial officer, succeeding David S. Wichmann after
having been executive vice president at Optum. (reuters.com)
Valeant repaid about $47.5 million of its term debt in a mandatory asset sale payment as required by
its lenders in order to fulfill the credit agreement amendment. (finance.yahoo.com)
Astellas has struck another drug repurposing agreement, collaborating with Excelra, an Indian
informatics company famous for its drug repurposing database and algorithms. (fiercebiotech.com)
Daiichi Sankyo and Charleston Laboratories announced that the FDA has accepted for review the
New Drug Application (NDA) for CL-108 for the relief of moderate to severe pain. (pharmabiz.com)
Terumo acquires Sequent Medical for $280 million. This deal helps Terumo expand its neurovascular
product line as Sequent makes an implant for treating brain aneurysms. (reuters.com)

2. Contact: Harald Schelenz Linkedin: https://de.linkedin.com/in/haraldschelenz
Mail: hs.healthcarenews@gmail.com Xing: https://www.xing.com/profile/Harald_Schelenz
page2
Regional Comparison
Focus on Europe
95%
97%
99%
101%
2016-06-13 2016-06-14 2016-06-15 2016-06-16 2016-06-17
Europe North America Asia/Pacific
Ha i g a look at a regio al split up of the orld’s iggest listed health are o panies, it becomes
clear that the overall tendency was quite negative, yielding -2.2% this week for the global
development. Asia/Pacific took a major hit by decreasing -4.4%, whereas Europe suffered from a
decline of -3.2% and North America experienced a loss of -1.3% on a weekly basis.
Weekly News Wrap-Up: HEALTH CARE Industry
No. 16
2016-06-18
Christian Hansen Elekta Genmab Getinge Grifols
Indivior Novo Nordisk Orion Sonova Stada
SPOTLIGHT
FINANCIAL MARKET NEWS
The strongest performer from Europe in the weekly performance ranking is Indivior with an increase
of +4.4% while its one year performance reaches -14.7%. Second is Orion with a value gain of +2.0%
on a weekly basis while it shows a one year growth of +13.6%.
Regardi g this eek’s lo perfor ers fro Europe, the orst de elop e t experie ed Novo
Nordisk with a decrease of -7.4%, while its one year change amounts to -5.6%. In second place is
Stada with a loss of -6.0% on a weekly basis, whereas its one year increase reaches +50.5%.
top 5 companies closing price 1 week change 1 year change 1 week's high 1 week's low 1 year's high 1 year's low
Indivior 2.83 +4.49% -14.76% 2.88 2.62 3.89 1.61
Orion 34.32 +2.00% +13.60% 34.90 32.53 38.81 28.06
Elekta 6.37 -0.11% +8.19% 6.42 6.30 8.11 5.50
Christian Hansen 54.71 -0.79% +27.40% 54.96 52.97 61.59 42.22
Getinge 167.00 -0.81% -17.75% 167.87 164.60 226.30 164.60
flop 5 companies closing price 1 week change 1 year change 1 week's high 1 week's low 1 year's high 1 year's low
Novo Nordisk 45.68 -7.46% -5.69% 49.00 45.38 55.99 40.85
Stada 43.85 -6.07% +50.53% 46.31 42.56 49.46 28.07
Sonova 109.75 -5.81% -13.03% 115.12 109.57 130.71 100.91
Genmab 148.11 -5.77% +87.48% 155.70 140.18 172.50 67.98
Grifols 18.73 -5.55% +5.87% 19.38 18.73 22.96 17.38
Index closing price 1 week change 1 year change 1 week's high 1 week's low 1 year's high 1 year's low
STOXX® Europe 600
Health Care
698.45 -3.20% -12.12% 716.57 691.93 876.66 654.95
STOXX® North America 600
Health Care
815.94 -1.63% -9.53% 834.47 812.99 966.34 730.68
STOXX® Asia/Pacific 600
Health Care
437.37 -4.42% +15.10% 453.74 434.83 461.29 349.32
STOXX® Global 1800
Health Care
712.94 -2.28% -8.60% 732.53 711.29 842.76 647.94